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The production of an anterior myocardial infarction as part
of an experimental animal model for sudden death was
burdened by a persistently elevated mortality rule (30%)
despite the use of traditional antiarrhythmic drugs . Moe.
tality was reduced when tocainide 1600 mg three times
daily) was empirically administered for 4 days before and 4
days after myocardial infarction. Retrospective analysis
showed that mortality at 4 days after infarction was signif .
icandy, lower in the tocainidedreated dogs than In the
preceding large group of dogs that had not been so treated
(5 19%] of 55, versus 64 132%] of 199, p < 0.01). This
difference was still evident 30 days after myocardial infe-_-
tion (13 [24%] of 55 versus 03 (42%] of 199 ; p < 0.05).
This observation led to the present prospective study in
106 dogs with a similar protocol but with a randomized
sequence. At 4 days after myocardial infarction, the mor-
tally, rate was 55% lower in the tocainide group than in the
Sudden cardiac death in patients with ischemic heart disease
remains a baffling problem despite apparent progress in
the understanding of cardiac electrophysiology and the avail-
ability of new and potent antiarrhythmic drugs. As the
results of the Cardiac Arrhythmias Suppression Trial (I)
indicate with finality, therapy with a drug that suppresses
ventricular arrhythmias does not necessarily reduce the risk
for sudden death . In fact, the question of antiarrhythmic
versus antifibrillatory effects is as open as ever (2)
.
There-
fore, a serendipitous experimental observation seemed
worth pursuing further si5d has generated a prospective
study that shows increased survival in the postinfarction
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control group (7 [12.5%] of 56 versus 14120%] of 50; p <
0.05) . During the 10 day' after treatment withdrawal 9
(10"0) of 49 dogs in the tocainide group died compared with
only 2 (5%) of 36 in the control group. This rebound in
mortality produced similar survival figures in the two
groups at 14 and at 30 day after infarction when mortality
vas 30% (17 of 56) in the :acalnide group and 34% (17 of
50) in the control group. The forelock, plasma levels were
7 .4 ± 4 pglmt the day before infarction and 7 .2 ± 3
Jag/ml
3 days after infarction.
This study indicates that mortality in the first few days
after myocardial infarction can be reduced by tocainide .
The results may be of potential interest for the out of
hospital management of patients with a recent myocardial
infarction.
(J Am Coll Cordial 1990;16:1475-80)
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period after treatment with tocainide, a class IB antiarrhyth-
mic drug (3).
A high mortality rue in the early days after myocardial
infarction was the rain problem encountered in the prepa-
ration of our experimental animal model for the study of
sudden cardiac death (4,5) . Within 4 days after the produc-
tion of a myocardia. infarction by ligation of the left anterior
descending coronary artery, almost 30^io of dogs were regu-
larly lost because of sudden death
. This early postinfarction
mortality rate had renamed constant over the years and had
not been obviously affected by the use of either quinidine or
prucainamide. An at :empt was then made with the use of
tocainide. To our ssrprise, a marked reduction in the postin-
farction mortality rate became evident and administration of
tocainide became routine in our laboratory . The striking
reduction in mortality after treatment with tocainide and
the potential clinical relevance of this finding led us to de-
sign a randomized prospective study to assess if tocainide
could effectively reduce mortality in the first few days after
infarction .
0735-1097,90153 .50
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Methods
Mongrel dogs (15 to 20 kg) conditioned for chronic study
were purchased from a United States Department of Agri-
culture registered animal dealer.
Surgical preparation and coronary artery seclusion. The
procedure describing the surgically created myocardial in-
farction has been presented in detail elsewhere (4,5) . In
brief, anesthesia was induced by thiamylal sodium (25 mg/kg
body weight) and maintained by respirator-assisted inhala-
tion of anesthetic (halothzne, 0 .5% to 1 .5%) in an oxygen-
nitrous oxide mixture. A thoracotomy was performed with
aseptic procedure in the fourth intercostal space . Through
this opening a tygon catheter was inserted in the aortic arch
and the pericardium was opened and suspended in a cradle
.
The circumflex branch of the left coronary artery was
dissected free from the surrounding tissue for 2 cm at its
origin. A 20 MHz Doppler flow probe and a pneumatic
occluder were positioned around the vessel . The instrumen-
tation in the aortic arch and around the left circumflex
coronary artery was part of the preparation of a long-term
animal model for the study of sudden cardiac death (4,5) and
was never used during the 30 days of follow-up .
The anterior descending branch of the left coronary
artery was dissected for a short distance immediately prox-
imal to the first diagonal branch
. The vessel was then
occluded in two stages, as described by Harris (6). A
stenosis was initially performed by tying together the vessel
and a 21 gauge needle, which was then removed . After 20
min the vessel was completely ligated. The pericardium was
loosely sewn and the chest was closed
. The distal ends of the
instrumentation were tunneled under the skin and exterior-
ized on the dorsal surface of the neck . Immediately after
endotracheal extubation, every dog received a fast-acting
analgesic, pentazocine lactate (Talwin), I mg/kg intramuscu-
larly, followed 4 h later by a longer-acting analgesic, nalbu-
phine hydrochloride (Nubain), 0
.5 mg/kg intramuscularly .
Appropriate antibiotic therapy was also administered . The
same technical staff performed most of the surgical interven-
tions. Duration of surgery rarely exceeded 3 h . The electro-
cardiogram was continuously monitored during surgery and
during recovery from anesthesia.
We adhered strictly to the guidelines for the appropriate
care and use of research animals established by the National
Institutes of Health, the American Physiological Society and
the American Heart Association .
Tocainide plasma level determination, Tocainide plasma
levels were assessed by a modification of the method de-
scribed by Shihabi et at. (7)
. Blood samples were collected
from the cephalic vein and centrifuged . Plasma samples were
thawed and aliquots were filtered through Centrifree (Ami-
con) filter tubes to deproteinize the samples . Two hundred
microliters of deproteinized plasma was mixed with an equal
volume of acetonitrile and refiltered in microfuge tubes
. The
high-pressure liquid chromatography instrumentation con-
sisted of a BAS model 400 (Bioanalytical Systems) . The
mobile phase was delivered at a rate of 1 .3 ml/min onto a
Syneropak SCD-100 column (150 x 4 .6 mm, 5 pg particles)
(Synchrom) . Samples were delivered into a 10 µl loop by a
Precision auto sampler, model LC-2000 (Dynatech). The
column eluent was detected with an ultraviolet detector with
a 229 nm filter.
The mobile phase consisted of 25 mM ammonium phos-
phate buffer in 24% acetonitrile, pH 7 .3 . Stock tocainide
standard was 100 mg/liter in acetonitrile . Working standards
were made from the stock standard by dilution in water.
To obtain control plasma samples, known amounts of
tocainide were added to plasma samples from control dogs .
These samples, prepared in the same manner as others, were
used to determine percent recovery . We found the assay to
be linear (r = 0.99) between I and 20 mg/liter and the
recovery to be 100% . The between-assay variability was
9 .5% .
Experimental protocol. The study consisted of two parts :
In the first part a retrospective analysis compared the
mortality rate that occurred after myocardial infarction in
199 consecutive dogs with that of a second group of 55 dogs
identically prepared but treated with tocainide . During the
period in which these 55 dogs were studied, 12 additional
dogs were prepared identically without treatment with
tocainide to verify that the mortality rate had not changed
over time
. In the second part of the study 134 dogs were
prospectively randomized to either myocardial infarction
and treatment with tocainide or myocardial infarction alone .
Tocainide (600 mg twice a day at 8 AM and 5 PM) was
given orally beginning 4 days before the production of
infarction and continuing for 4 days after. The time of
surgery allowed the dog to receive one tablet in the morning
just before surgery and one in the late afternoon after
recovery from anesthesia. Dogs in the control group did not
receive any antiarrhythmic drugs .
Blood samples for the assay of rocainide plasma levels
were taken in the afternoon the day before surgery and on
the 3rd day after surgery (both before tocainide administra-
tion).
Mortality that occurred in the very early phase of the
myocardial infarction was calculated separately from mor-
tality after recovery from anesthesia
. Follow-up continued
for 30 days after infarction .
All dogs included in the study were considered to be in
good condition by the technical and veterinary staff on the
basis of daily inspection
. A necropsy was performed in all
dogs that died during follow-up
. If the death was determined
to be secondary to extracardiac conditions, that is, over-
whelming infection or technical problems, the dog was
excluded from the analysis. Only cardiac-related deaths
were analyzed
. Extracardiac mortality was approximately
3% .
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Figure 1 . Cardiac mortality at 4 days after myocardial infarction in
the retrospective study of 211 dogs that did not receive tocainidc
(groups I and 3) and of 55 tccainide-treated dogs (group 2).
Statistical analysis
. Curves of survival after myocardial
infarction were calculated according to the method of Cutler
and Ederer (8) . Differences in mortality rate at different
times after coronary artery ligation were compared by
chi-square test. A p < 0 .05 was considered significant for the
differences tested .
Results
Retrospective Study
A total of 266 dogs recovered from anesthesia and were
used for this analysis
. Within the total group of dogs, three
subgroups were identified . Group I (n = 199) included the
dogs which were operated on before locainide treatment
started; group 2 dogs (n = 55) received tocainide and were
operated on after group 1 ; group 3 dogs (n = 12) did not
receive tocainide and were operated on during the same time
frame as group 2 dogs
. Mortality was calculated on the basis
of the information on surgery, recovery phase and necropsy,
as provided by the records.
Early mortality
. In group 1, 64 (32%) of the 199 dogs died
during the first 4 days after myocardial infarction . In con-
trast, only 5 (9%) of the 55 dogs in group 2 died during the
first 4 days after myocardial infarction . The difference in
mortality rate between the two groups was highly significant
(p < 0
.01)
. In group 3, 6 (50%) of the 12 dogs died within 4
days of infarction, thus confirming the elevated mortality
rate as a consequence of the anterior infarction in nontreated
dogs (group) (Fig. 1).
Later mortality. In group 1, 19 of the 135 dogs that
survived the first 4 days subsequently died . This resulted in
a mortality rate (14%) markedly lower than the initial 32% .
An opposite trend was observed in group 2, where mortality
VANOLI ET AL.
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Figure 2. Cardiac mortality at 4 days after myocardial infarction in
the prospective study in the control group (n = 50) and the
tocainidc-heated group (n = 56) .
in the second part cf the follow-up was 16% (8 of the 50 dogs
that survived the first part of the follow-up), almost double
the initial 9% . Thirty days after infarction the difference in
mortality between the two groups, although less impressive,
was still significant (83 142%) of 199 versus 13 124%) of 55 ;
p < 0 .05).
Prospective Study
A total of 134 dogs were used in the prospective study ; 71
were treated with tocainide and 62 served as a control group .
Five dogs (two in the control group and three in the
locainide-treated group) were excluded from the study be-
cause they died of technical issues.
Early mortality. The incidence of ventricular fibrillation
in the first 3 h after infarction was not different in the two
groups of dogs, because it occurred in 11(18%) of 61 control
dogs and in 12 (18%) of68 tocainide-treated dogs . Among the
dogs that survived the first 3 h after myocardial infarction,
mortality in the subsequent 4 days was reduced by 55% in
the tocainide-treated group, as compared with the control
group : 7 (12 .5%%) of 56 versus 14 (28%) of 50; p < 0.05 (Fig .
2) .
Analysis of survival curves (Fig
. 3) indicates that at 48 h
after myocardial infarction mortality was already markedly
reduced in the treated as compared with the control group .
After tocainide therapy was discontinued on the 5th day
after myocardial infarction, mortality in the tocainide group
progressively increased, so that the two survival curves
became very similar .
Later mortality. During the 10 days after cessation of
treatment with tocainide, the mortality rate in the surviving
dogs was 18% (9 of 49) in !he group treated with tocainide, as
1478
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Figure 3 . Survival curves of the control and tocainide-treated
groups in the prospective study . Mortality in the Isl day after
myocardial infarction incorporates dogs that died during the peri-
operative phase, that is, the first 3 h after occlusion of the left
anterior descending coronary artery. The cessation of treatment 4
days after infarction is indicated by the vertical dotted line. Survival
in the tocainide-treated group is significantly
higher during the first
4 days after infarction. After treatment is withdrawn, mortality
increases in the tocainide group and the two curves become almost
indistinguishable .
opposed to 5% (2 of 36) in the control group . This resulted in
a total mortality that was not different iii the two groups of
dogs at 14 days after myocardial infarction : 16 (29%) of 56 in
the tocainide group versus 16 (32%) of 50 in the control
group .
Only two dogs (one in each group) died during the
remaining 15 days of observation and the mortality rate at 30
days after infarction was 30% (17 of 56) in the tocainide
group and 34% (17 of 50) in the control group
.
Tocainide plasma levels . Tocainide plasma levels were
measured in 22 dogs before and after the production of the
anterior myocardial infarction
. Mean plasma levels of
tocainide were 7.4 ± 4
jug/ml
(range 2 .7 to 15.7) before
surgery and 7 .2 t 3 pest (range 4 to 16.8) after surgery .
Discussion
This study shows that oral administration of tocainide can
effectively reduce mortality in conscious dogs during the first
4 days after a myocardial infarction . This protective effect
begins only after the very early phase of a coronary
artery
occlusion.
Tocainlde plasma levels. The dosages used in the present
study resulted in plasma levels of tocainide within ranges
considered therapeutic in human studies (9-13) .
These levels
- 1-re lower than those attained in other experimental
studies
that reported an antiarrhythmic effect of tocainide . Specifi-
cally, in one study (14-16) tocainide was able to increase
ventricular fibrillation threshold
only when plasma levels
were > l0 pg*ml
. In an open chest preparation sympathetic
activity and circulating cathecolamines are likely to be
markedly increased and this increase may explain, at least in
part, the high dosages of tocainide needed to observe a
protective effect in this latter study. In another study (I5),
however, tocainide concentration of 5 to 10 pg/ml in the
perfusing solution suppressed arrhythmias due to enhanced
automaticity induced by epinephrine in Purkinje fibers . In
the present study in conscious dogs, we tested the efficacy
of
tocainide with dosages leading to plasma levels that can be
attained clinically without significant side effects .
Mortality In the acute phase of myocardial infarction.
Tocainide did not reduce the incidence of ventricular fibril-
lation between the two stages of coronary artery occlusion
or in the first 3 h after complete ligation of the artery .
Arrhythmias that occur at this time are thought to depend on
either reentry or abnormal automaticity (17,18) .
Reflex sympathetic activation that occurs during the first
few minutes of acute myocardial ischemia (19) plays an
important role in the genesis of malignant arrhythmias (20-
23). As a consequence, drugs devoid of any antiadrenergic
effect may be ineffective in preventing ventricular fibrillation
and sudden death in the very early phase of acute myocardial
ischemia . This concept is supported by data obtained in a
feline preparation in which malignant arrhythmias can be
consistently induced by the combination of transient coro-
nary artery occlusion and brief stimulation of the left stellate
ganglion (24) . This experimental model allows evaluation of
antiarrhythmic drugs by internal control analysis . Although
amiodarone and antiadrenergic and calcium channel block-
ing drugs provided effective protection in this model, class
IB and IC antiarrhythmic drugs failed to prevent ventricular
tachyarrhythmias (25-27) . The two class
III agents tested
were lidocaine and mexiletine, congeners of tocainide
. A
clinical counterpart of this observation is represented by the
evidence that lidocaine is frequently ineffective when admin-
istered in the first few hours after the beginning of symptoms
of acute myocardial ischemia
(28).
For these reasons the
failure of tocainide to provide any protection during the very
early phase of acute myocardial ischemia was not unex-
pected .
Mortality In the subacute phase of myocardial infarction
.
The efficacy of tocainide in reducing mortality in the sub-
acute phase after myocardial infarction represents novel
information. Although arrhythmia monitoring was not per-
IACC Vol. 16, No. 6
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formed during the recovery phase after
infarction.the dogs
were visited by the personnel three to four limes a day ; the
dogs that died included in the study were considered in good
condition before they were found dead . Thus . it seems
legitimate to consider that most of the deaths that occurred
in our study were sudden
.
There is clinical and experimental evidence that indicates
a powerful antiarrhythmic effect of tocainide but there are
few studies relevant to the problem of sudden cardiac death
that involve tocainide . In two previous experimental studies
(16,29) locainide abolished ventricular tachyarrhythmias de-
pendent on chronic ischemia induced by an ameroid con-
strictor (16) and significantly reduced the inducibility of
ventricular tachycardias in conscious dogs that underwent
an electrophysiologic study 7 to 30 days after a myocardial
infarction (29) .
In clinical studies of postinfarction patients or of patients
with coronary artery disease, a remarkable antiarrhythmic
effect of tocainide was also observed
(9-I3) ;
nevertheless .
such an effect was not associated with a reduced mortality
(13). Indeed, in the only prospective study conducted with
tocainide in 56 tocainide-treated and 56 placebo-treated
patients (13), a similar mortality rate was noted during the 6
months of follow-up . It is fair to say that of the four deaths
in the tocainide-treated group, only one occurred in a patient
with tocainide plasma levels within the therapeutic range
.
Thus, there is no clear evidence that conclusively demon-
strates the effect of tocainide on the incidence of sudden
death in patients recovering from a myocardial infarction .
Mechanisms of tocainide protective effect . The strikingly
protective effect of tocainide in the subacute phase of the
myocardial infarction in our study was rather unexpected
based on current knowledge but it does not contradict the
lack of effect on the tachyarrhythmias of the very early
phase after coronary artery occlusion
. Indeed, at this time
reflex sympathetic hyperactivity . which plays an important
role in the genesis of these arrhythmias, has already suh-
sided (30) and other electrophysiologic mechanisms have
became important (6,31) . The polymorphic ventricular (achy-
cardias usually observed in dogs during the first days after
myocardial infarction depend mostly on abnormal automa-
ticity and on triggered activity (32,33) .
Relevant to this is the finding that tocainide suppresses
arrhythmias due to enhanced automaticity of Purkinje fibers
(15). This electrophysiologic effect probably depends on the
fact that class III antiarrhythmic drugs reduce transmem-
brane inward Na' currents and lead to a reduction
of
intracellular sodium; as a consequence, intracellular Ca"
concentration decreases (34) . High levels of intracellular
Cat'
can enhance triggered activity (35) .
Long-term treat-
ment with class IB drugs may reduce and should reduce the
incidence of rapid ventricular tachycardias dependent on
triggered activity .
The efficacy of tocainide in the subacate phase
of
ntyo-
cordial isthtrciioe is indicated by two different
aspects f,-
data . the reduced mortality during the 4 days after myocar-
dial infarction associated with treatment and the rather
dramatic increase in mortality after tocainide withdrawal .
Indeed, as demonstrated by the survival curves (Fig. 3),
within a few days after cessation of treatment any distinction
between the placebo- and tocainide-treated groups had dis-
appeared . It is tempting to postulate that the dogs that died
after cessation of treatment with tocainide would have died
earlier if they had not been treated .
Implications
. This study indicates that mortality in the
few days immediately after myocardial infarction can be
significantly reduced by treatment with tocainide
. The study
was not designed for and provides no data to suggest that
this beneficial effect would last beyond the subacute phase .
At that time different electrophysiologic mechanisms be-
come involved in the genesis of lethal arrhythmias (including
transient ischemic episodes, perturbations in autonomic
activity and abnormal mechanical stretch) that may no
longer be preventable by a drug like tocainide
. as are the
arrhythmias of the very early phase. The possibility. not
raised before, that tocainide may decrease the probability of
a lethal arrhythmia in a period up to 2 weeks after a
myocardial infarction may be of clinical interest for patients
managed in an out of hospital s. .ting.
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